Development of therapies for autoimmune disease at Stanford: A tale of multiple shots and one goal

Immunologic Research

Volumn 58, Issue 2-3, 2014, Pages 307-314

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Altered peptide ligand; Angiotensin converting enzyme; Immunotherapy; Natalizumab; Statins; Therapeutic antibody

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; TREATMENT INDICATION; ANIMAL; ART; AUTOIMMUNE DISEASES; DRUG EFFECTS; HISTORY; IMMUNITY; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGY; MEDICAL SCHOOL; RESEARCH; TRENDS; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CALIFORNIA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOLOGICAL SYNAPSES; RESEARCH; SCHOOLS, MEDICAL;

EID: 84901388512     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8509-0     Document Type: Review

References (55)

1. McDevitt HO, Sela M. Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med. 1965;122(3):517-31.
2. McDevitt HO, Tyan ML. Genetic control of the antibody response in inbred mice. Transfer of response by spleen cells and linkage to the major histocompatibility (H-2) locus. J Exp Med. 1968;128(1):1-11.
3. Hedrick SM, Cohen DI, Nielsen EA, Davis MM. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature. 1984;308(5955):149-53. (Pubitemid 14129555)
4. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983;304(5921):30-4. (Pubitemid 13063101)
5. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306(9):517-22. (Pubitemid 12175745)
6. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG. AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science. 1986;232(4754):1123-7. (Pubitemid 16050799)
7. Kimoto M, Fathman CG. Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation. J Exp Med. 1980;152(4):759-70. (Pubitemid 10010864)
8. Zamvil S, Nelson P, Trotter J, Mitchell D, Knobler R, Fritz R, Steinman L. T cell clones specific for myelin basic protein induce chronic relapsing EAE and demyelination. Nature. 1985;317:355-8. (Pubitemid 15232523)
9. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard J. T cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986;324:258-60. (Pubitemid 17180453)
10. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature. 1981;292(5818):60-1. (Pubitemid 11048545)
11. Steinman L, Rosenbaum JT, Sriram S, McDevitt HO. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA. 1981;78:7111-4.
12. Waldor M, Sriram S, McDevitt HO, Steinman L. In vivo therapy with monoclonal anti I-A antibody suppresses immune response to acetylcholine receptor. Proc Natl Acad Sci USA. 1983;80:2713-7. (Pubitemid 13093379)
13. Waldor MK, Hardy RR, Hayakawa K, Steinman L, Herzenberg LA, Herzenberg LA. Disappearance and reappearance of B cells following in vivo treatment with monoclonal anti I-A antibodies. Proc Natl Acad Sci USA. 1984;81:2855-8. (Pubitemid 14106226)
14. Waldor M, Mitchell D, Kipps J, Herzenberg LA, Steinman L. Importance of immunoglobulin isotype in therapy of EAE with monoclonal anti-CD4 antibody. J Immunol. 1987;139:3660-4. (Pubitemid 18013637)
15. Alters SE, Steinman L, Oi VT. Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro: chimeric antibodies lyse low density CD4 + cells. J Immunol. 1989;142:2018-23. (Pubitemid 19081557)
16. Jonkers M, van Lambalgen R, Mitchell D, Durham SK, Steinman L. Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies. J Autoimmun. 1988;1:399-414.
17. Acha-Orbea H, Mitchell DJ, Timmerman L, Wraith DC, Waldor MK, Tausch GS, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988;54:263-73.
18. Oksenberg JR, Stuart S, Begovich AB, Bell R, Erlich H, Steinman L, Bernard CCA. Limited heterogeneity of rearranged T cell receptor transcripts in brains of multiple sclerosis patients. Nature. 1990;345:344-6.
19. Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, Shimonkevitz R, Sherritt M, Rothbard J, Bernard CCA, Steinman L. Selection for T cell receptor Vb-Db-Jb gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 1993;362:68-70. (Pubitemid 23087292)
20. http://www.nytimes.com/1990/05/24/us/new-findings-on-nerve-damage-may- help-treat-multiple-sclerosis.html.
21. Killestein J, Olsson T, Wallström E, Svenningsson A, Khademi M, Blumhardt LD, Fagius J, Hillert J, Landtblom AM, Edenius C, Arfors L, Barkhof F, Polman CH. Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol. 2002;51(4):467-74. (Pubitemid 34260776)
22. Waldor MK, Hardy R, Herzenberg LA, Herzenberg LA, Lanier L, Sriram S, Lim M, Steinman L. Reversal of EAE with monoclonal antibody to a T cell subset marker (L3T4). Science. 1985;227:415-7. (Pubitemid 15153498)
23. Alters SE, Sakai K, Steinman L, Oi VT. Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. J Immunol. 1990;144(12):4587-92. (Pubitemid 20224089)
24. Lindsey JW, Hodgkinson S, Mehta R, Siegel RC, Mitchell D, Lim M, Piercy BA, Dorfman L, Enzmann D, Steinman L. Phase I clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology. 1994;44:413-9. (Pubitemid 24098136)
25. van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial. Neurology. 1997;49(2):351-7.
26. Wraith DC, McDevitt HO, Steinman L, Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell. 1989;57:709-15. (Pubitemid 19149811)
27. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell. 1989;59:247-55. (Pubitemid 19264371)
28. Karin N, Mitchell D, Ling N, Brocke S, Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of Interferon-- and TNF-a production. J Exp Med. 1994;180:2227-37.
29. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L, the APL in Relapsing MS Study Group. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nat Med. 2000;6(10):1176-82.
30. Pedotti R, Mitchell D, Wedemeyer J, Karpuj M, Chabas D, Hattab E, Tsai M, Galli SJ, Steinman L. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol. 2001;2:216-22. (Pubitemid 33705997)
31. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6(10):1167-75.
32. Yednock T, Cannon C, Fritz L, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature. 1992;356:63-6.
33. Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70:172-82.
34. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
35. Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol. 2012;199:413-6. doi:10.1083/jcb.201207175.
36. Steinman L. Immunology of relapse and remission in multiple Sclerosis. Annu Rev Immunol. 2014;32:257-81.
37. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-80.
38. Ho P, Fontoura P, Ruiz P, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol. 2003;171:4920-6. (Pubitemid 37310616)
39. Robinson WH, Fontoura P, Lee BJ, de Vegvar HEN, Tom J, Pedotti R, DiGennaro C, Mitchell DJ, Fong D, Ho PK, Ruiz P, Maverakis E, Stevens D, Bernard CCA, Olsson T, Martin R, Kuchroo VK, van Noort JM, Genain CP, Utz PJ, Garren H, Steinman L. Reverse genomics: protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol. 2003;21:1033-9. (Pubitemid 37064732)
40. Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol. 2008;181:8298-307.
41. Garren H, Robinson W, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L, the BHT-3009 Study Group. Phase 2b trial of a DNA vaccine encoding myelin basic protein in relapsing multiple sclerosis. Ann Neurol. 2008;63(5):611-20.
42. Steinman L. The road not taken: antigen-specific therapy and neuroinflammatory disease. JAMA Neurol. 2013;1:1-2. doi:10.1001/jamaneurol.2013. 3553.
43. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes. 1998;47:1857-66. (Pubitemid 28549191)
44. Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King R, Robinson WH, Utz PJ, Garren H, the BHT 3021 Investigators, Steinman L. Plasmid encoded proinsulin preserves C-peptide while specifically reducing proinsulin specific CD8 T cells in type 1 diabetes. Sci Transl Med. 2013;5(191):191ra82. doi:10.1126/scitranslmed.3006103.
45. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-6.
46. Youssef S, Stuve O, Patorroyo J, Ruiz P, Radosevich J, Hur EM, Bravo M, Mitchell D, Sobel RA, Steinman L, Zamvil S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature. 2002;420:78-84. (Pubitemid 35291443)
47. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells providing a mechanism for modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203:401-12. (Pubitemid 43290849)
48. Chataway J Schuerer N, Alsanousi A, et al Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebocontrolled, phase 2 trial. Lancet Neurol. 2014;6736(13):62242-4. http://dx.doi.org/10.1016/S0140.
49. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS, ITN STAyCIS Study Group, ITN020AI Study Management Team. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012;78(15):1171-8. doi:10.1212/WNL.0b013e31824f7fdd.
50. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin converting enzyme induces potent regulatory T cells and modulates TH1 and TH17-mediated autoimmunity. Proc Natl Acad Sci USA. 2009;106:14948-53.
51. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Investig. 2010;120(8):2782-94.
52. Chabas D, Baranzini S, Mitchell D, Bernard CCA, Rittling S, Denhardt D, Sobel R, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg J, Steinman L. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-5.
53. Ousman SS, Tomooka BH, Van Noort JM, Wawrousek EF, O'Conner K, Hafler DA, Sobel RA, Robinson WH, Steinman L. Protective and therapeutic role for aB-crystallin in autoimmune demyelination. Nature. 2007;448:474-9. (Pubitemid 47123511)
54. Kurnellas MP, Adams CM, Sobel RA, Steinman L, Rothbard JR. Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med. 2013;5(179):179ra42.
55. http://www.poetryfoundation.org/poem/171540.